Botanical Solution Inc. raises additional $7m in Series A funding round

Delaware-based Botanical Solution Inc. (BSI) has announced a new influx of $7 million in investment, bringing the total Series A funding to over $13 million. This follows Botanical Solution Inc.’s recent partnership with Croda to speed up the green, high-quality, pharmaceutical-grade production of QS-21 at kilogram scale under GMP standards. With proven biochemical equivalence to traditional QS-21 from Chilean soapbark trees, Botanical Solution Inc. aims to build a robust, sustainable supply chain for this gold standard vaccine adjuvant.

Investment Fuels Growth in Multiple Markets

The new investment will accelerate Botanical Solution Inc.’s ambitious expansion plans, specifically focusing on its flagship biopesticide product, Quillibrium. Target markets for Quillibrium include Mexico, Brazil, the United States, and the EU. Botanical Solution Inc.’s existing partnership with Syngenta has already resulted in a 50% YOY growth in adoption by effective growers in Chile and Peru, treating over 100,000 acres to date.

Proprietary Platform and Advanced Botanical Materials

Botanical Solution Inc. has developed a proprietary platform for the sustainable production of high-quality Advanced Botanical Materials (ABM). Their first such material, ABM-01, is produced from the plant Quillaja saponaria and serves as the active ingredient in both Quillibrium and the vaccine adjuvant QS-21. These high-quality botanical products have applications in blockbuster vaccines for Shingles, RSV, and Malaria.

Investment Led by Otter Capital, Joined by Latin American Investors

The latest funding round was spearheaded by Otter Capital and included participation from Latin American investors like Boldo SpA and Quebec LP, controlled by the Casanueva and Saval family offices, which are focused on high-tech and pharma investments, among other investors.

On Track for Human Vaccine Material Delivery

According to Botanical Solution Inc. CEO Gaston Salinas, the company is on track to start delivering GMP materials for human vaccines later this year. “BSI is fortunate to have a strong group of investors who are enthusiastic about our progress and vision to impact multiple industries through our breakthrough technology and truly sustainable products,” said Salinas.

This new funding puts Botanical Solution Inc. in a strong position to address significant challenges in both the pharmaceutical and agricultural sectors, offering sustainable solutions for vaccine adjuvants and modern agriculture disease control.